Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-1827
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma ; day:17 ; month:6 ; year:2022 ; pages:1-9
British journal of cancer ; (17.6.2022), 1-9
- Creator
-
Hollis, Robert L.
Croy, Ian
Churchman, Michael
Bartos, Clare
Rye, Tzyvia
Gourley, Charlie
Herrington, C. Simon
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41416-022-01874-8
- URN
-
urn:nbn:de:101:1-2022081622230089112779
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hollis, Robert L.
- Croy, Ian
- Churchman, Michael
- Bartos, Clare
- Rye, Tzyvia
- Gourley, Charlie
- Herrington, C. Simon
- SpringerLink (Online service)
Other Objects (12)
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Low-grade Serous Ovarian Carcinoma
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Low-grade Serous Ovarian Carcinoma
A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
First-Line Management of Advanced High-Grade Serous Ovarian Cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Tumor Evolution and Heterogeneity in High-Grade Serous Ovarian Cancer
Principles of dormancy evident in high-grade serous ovarian cancer
Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma
Developing a DNA Methylation Signature to Differentiate High-Grade Serous Ovarian Carcinomas from Benign Ovarian Tumors
Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma
MRI for differentiating ovarian endometrioid adenocarcinoma from high-grade serous adenocarcinoma
No evidence for PALB2 methylation in high-grade serous ovarian cancer
Low-grade Serous Ovarian Carcinoma